8-K 1 form8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

                                               

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  August 13, 2020

 

ANIXA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

000-11254

11-2622630

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer

Identification No.)

 

 

3150 Almaden Expressway, Suite 250

San Jose, CA

95118

(Address of principal executive offices)

(Zip Code)

 

 

Registrant’s telephone number, including area code:  (408) 708-9808

                                                                                               

(Former name or former address, if changed since last report)

                                               

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

      
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

      
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

      
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


                     Securities registered pursuant to Section 12(b) of the Act:  

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

ANIX

 

The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

1


 

Item 5.07         Submission of Matters to a Vote of Security Holders.

 

On August 13, 2020, Anixa Biosciences, Inc. (the “Company”) completed its 2020 annual meeting of stockholders (the “Annual Meeting”). The number of shares of stock entitled to vote at the Annual Meeting was 23,521,336 shares of common stock (the “Voting Stock”). The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was 17,491,948 shares. At the Annual Meeting, the Company’s stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, David Cavalier, Emily Gottschalk, Dr. John Monahan, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company’s executive compensation, (iii) ratified the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2020 and (iv) approved an amendment to Article FOURTH of the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares of common stock from 48,000,000 to 100,000,000. The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

 

Proposal No. 1 – Election of directors

 

Dr. Amit Kumar, Dr. Arnold Baskies, David Cavalier, Emily Gottschalk, Dr. John Monahan and Lewis H. Titterton, Jr. were elected to serve until the 2021 annual meeting of stockholders or until their successors are elected and qualified or until their earlier resignation or removal. The voting results were as follows:

 

Nominee

Shares Voted For

Shares Withheld

Broker Non-Vote

Dr. Amit Kumar

8,113,395

206,081

9,172,472

Dr. Arnold Baskies

8,242,514

76,962

9,172,472

David Cavalier

8,242,651

76,825

9,172,472

Emily Gottschalk

8,249,455

70,021

9,172,472

Dr. John Monahan

8,242,474

77,002

9,172,472

Lewis H. Titterton, Jr.

8,246,516

72,960

9,172,472

 

Proposal No. 2 – Approval, by non-binding advisory vote, of the Company’s executive compensation

 

The Company’s executive compensation, by non-binding advisory vote, was approved. The voting results were as follows: 

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

7,642,807

558,359

118,310

9,172,472

 

Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm

 

The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2020 was ratified. The voting results were as follows: 

 

Shares Voted For

Shares Voted Against

Shares Abstaining

Broker Non-Vote

17,446,149

30,586

15,213

0

  

Proposal No. 4 – Increase of authorized shares of common stock

 

2


 

The amendment to Article FOURTH of the Certificate of Incorporation to increase the number of authorized shares of common stock from 48,000,000 to 100,000,000 was approved. The voting results were as follows: 

 

Shares Voted For

Shares Voted Against

Shares Abstaining

Broker Non-Vote

13,589,302

3,725,832

176,814

0

 

Item 5.03         Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

            On August 14, 2020, following receipt of stockholder approval at the Annual Meeting, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 48,000,000 to 100,000,000, effective August 17, 2020.The Certificate of Amendment is attached to this Current Report as Exhibit 3.1.  All descriptions of the Certificate of Amendment herein are qualified in their entirety to the text of Exhibit 3.1 hereto, which is incorporated herein by reference.

 

Item 7.01         Regulation FD Disclosure.

 

            Attached as Exhibit 99.1 to this Current Report is the form of presentation of the Company which was used by management at its Annual Meeting. This presentation may be used by the Company in the future at meetings with investors, analysts or others, in whole or in part and possibly with modifications from time to time.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit No.             Description

 

3.1                   Certificate of Amendment

99.1                 Corporate Presentation

 

3


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Dated: August 17, 2020

 

ANIXA BIOSCIENCES, INC.

By: 

/s/ Amit Kumar

Name: Dr. Amit Kumar

Title: President and Chief Executive Officer

 

 

 

4